Allogeneic CD7-Targeted CAR-T Cell (RD13-02) Starts Second Phase-I Clinical Trial

RD13-02 uses specially engineered immune cells designed to remove certain immune cells believed to drive the autoimmune attack that damages insulin-producing beta cells. Researchers hope that by removing these harmful immune cells, the immune system may stop attacking the pancreas and allow remaining beta cells to continue working. This is a CAR-T therapy. CAR-T is a genetic engineering technique…